Bayer Pharma Aktiengesellschaft

Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Sterix Limited

Bayer Pharma Aktiengessellschaft

Bayer Animal Health Gmbh

Ulrich Bothe

Ulf Bömer

Judith Günther

Martin Lange

Holger Siebeneicher

Reinhard Nubbemeyer

Holger Steuber

Alexander Hillisch

Christian Stegmann

Alexandra Rausch

Duy Nguyen

Andrea Rotgeri

Olaf Peters

Peter Hauff

Arne Von Bonin

Christian Gege

Tobias Marquardt

Ingo Hartung

Oliver Martin Fischer

Walter Elger

Gerhard Siemeister

Dirk Kosemund

Anne Mengel

Georg Kettschau

Philip Lienau

Hans Briem

Wolfgang Schwede

Nicholas Charles Ray

Ulrich Lücking

Martina Schäfer

Karl-Heinz Thierauch

Birgitt Schneider

Antje Margret Wengner

Norbert Schmees

Sven Ring

Marcus Koppitz

Yolanda Cancho Grande

Nicole Schmidt

Christian Friedrich

Andreas Sutter

Judith Guenther

Wilko Regenhardt

Naomi Barak

Matthias Busemann

Judith Gunther

Ulf Boemer

Eberhard Unger

Roland Neuhaus

Jens Nagel

Gerd Schubert

Olaf Prien

Peter Droescher

Bernd Menzenbach

Martin Krueger

Nico Bräuer

Ulrike Fuhrmann

Guenter Kaufmann

Gudrun Reddersen

Horst Irlbacher

Karl H Thierauch

Martin Krüger

Ulrich Luecking

Lothar Sobek

Jerzy Adamski

Vladimir Patchev

Hans-Udo Schweikert

Oliver Von Ahsen

Gabriele Moeller

Carsten Moeller

Anja Schmidt

Pascal Savy

Gernot Langer

Gerald Beddies

Maria De Lourdes Mottier

Adrian Foster

Jörn Krätzschmar

Krolikiewicz Konrad

Stefan Joachim Jodl

Birgit Schneider

Andrea Rosinus

Isabella Gashaw

Nico Brauer

Martina Schafer

The present application relates to the use of substituted indazoles for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially for treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs

The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).

Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

The present invention relates to novel benzimidazole derivatives of the general formula (I), to processes for their preparation and to their use for preparing pharmaceutical compositions for the treatment of disorders and indications associated with the EP4 receptor.

Benzimidazole derivatives as EP4 ligands

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, COPD and psoriasis.

Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments

The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis. 

Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)

The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.

3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments

The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R, R, R, R, R, and Rare as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament. Said compounds have an anti-tumour action. 

2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action

The present invention relates to 2-arylthiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof 

2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals

Growing community of inventors

Berlin, Germany

Ulrich Bothe